癌症研究
生物
微卫星不稳定性
癌症
表观遗传学
甲基转移酶
肺癌
免疫疗法
基因
遗传学
肿瘤科
医学
甲基化
微卫星
等位基因
作者
Guoning Chen,Peijie Chen,Jianwen Zhou,Guangcheng Luo
出处
期刊:Combinatorial Chemistry & High Throughput Screening
[Bentham Science]
日期:2023-01-01
卷期号:26 (1): 83-92
被引量:6
标识
DOI:10.2174/1386207325666220221092318
摘要
Pan-cancer analysis is an efficient tool to obtain a panoramic view of cancer- related genes and identify their oncogenic processes, facilitating the development of new therapeutic targets. Lysine methyltransferase 2D (KMT2D), acting as a major enhancer coactivator for mammalian cells, is one of the most frequently mutated genes across various cancer types and is considered an oncogene and a rationale for epigenetic therapeutic targets.This study was designed to explore the potential role of KMT2D in human cancer through a pan-cancer analysis.The expression of KMT2D was assessed in normal tissues and cell lines, and pancancers from The Cancer Genome Atlas (TCGA), Cancer Cell Line Encyclopedia (CCLE), and Genotype-Tissue Expression (GTE) datasets were used to explore its correlation with prognosis, immune cell infiltration, tumor mutation burden, microsatellite instability, and mismatch repair.KMT2D expression was heterogeneous across different cancer types. Increased KMT2D indicated a worse prognosis in adrenocortical carcinoma (ACC), brain lower-grade glioma (LGG), and mesothelioma (MESO), while patients with high KMT2D expression showed better outcomes in renal clear cell carcinoma (KIRC). Moreover, KMT2D expression was positively correlated with immune cell infiltration and negative tumor mutation burden in multiple cancers. In addition, a significant correlation between KMT2D and immune checkpoint-related genes or mismatch repair genes was identified.These findings support the hypothesis that KMT2D is not only a potential biomarker for prognosis and immunotherapy response prediction but also an essential immune regulator in human cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI